focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

AIM Rule 17 Disclosure Schedule Two (g) Update

17 Jan 2014 07:00

RNS Number : 9140X
Phorm Corporation Limited
17 January 2014
 

17 January 2014

 

Phorm Corporation Limited ("Phorm" or the "Company")

 

AIM Rule 17 Disclosure Schedule Two (g) Update

 

Phorm (AIM: PHRM), a leading internet personalisation technology company, announces, in accordance with Rule 17 and Schedule Two (g) sub-paragraph (v) of the AIM Rules for Companies, that it has been notified of the following information by Lord Norman Lamont, Non-Executive Director of Phorm:

 

Lord Lamont was, until 19 October 2012, a director of Balli Group Plc ("Balli"), a private company incorporated in the UK. Balli was placed into administration on 20 March 2013 and Deloitte LLP were appointed as administrators.

 

In addition, Lord Lamont was, until 30 March 2009, a director of Pantin Hotels (Management) Limited, a private company incorporated in the UK, subsequently renamed Hallco 1063 Limited ("Hallco") on 7 May 2009. Hallco entered into a creditors' voluntary liquidation on 24 July 2009 with an estimated total deficit as regards creditors on that date of £116,438. Hallco was dissolved on 14 January 2011.

 

 

-ends-

 

Contact

 

Phorm Corporation Limited

 

Andy Croxson (analysts & investors) +44 20 3397 6001

 

UK Investors

Mirabaud Securities LLP +44 20 7321 2508 (Joint Broker)

 

Jason Woollard

Peter Krens

 

Liberum Capital +44 20 3100 2222 (Nominated Advisor and Joint Broker)

 

Chris Bowman

Richard Bootle

 

US Investors

Lippert Heilshorn and Associates +1 212 838 3777 (Investor Relations)

 

John Heilshorn

 

About Phorm

 

Phorm is a global personalisation technology company that makes content and advertising more relevant to the consumer. Phorm's innovative platform preserves user privacy and delivers a more interesting online experience.

 

Phorm's industry leading technology enables its ISP partners to offer a new type of online advertising platform and a free consumer internet content feature, ensuring more relevant advertisements and personalised content for opted-in users.

 

Phorm's advertising platform revolutionises current standards of online privacy, fully protecting the identity of consumers. Unlike virtually all other targeted advertising propositions, Phorm's solution is completely opt-in. Only those users consenting to the service are profiled and only ever on an anonymous basis.

 

Phorm's partners include leading Internet Service Providers (ISPs), Publishers, Advertising Networks and Advertisers.

 

Phorm, under a predecessor holding company, was admitted to the AIM market of the London Stock Exchange in 2004.

 

For more information, please visit: www.phorm.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFFSIWFLSEEF

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.